| LP417649-3 | post Direct Oral Anticoagulants neutralization | CHALLENGE | |
| LP417650-1 | Dilution factor | COMPONENT | 1 |
| LP417651-9 | HLA-A and B and C (class I) IgG with prozone effect | COMPONENT | 1 |
| LP417652-7 | HLA-A and B and C (class I) IgG high risk | COMPONENT | 1 |
| LP417655-0 | HLA-DP and DQ and DR (class II) IgG with prozone effect | COMPONENT | 1 |
| LP417656-8 | HLA-DP and DQ and DR (class II) IgG high risk | COMPONENT | 1 |
| LP417658-4 | HLA-DRB3 and HLA-DRB4 and HLA DRB5 | COMPONENT | 6 |
| LP417659-2 | HLA-DQB1 Ab.IgG | COMPONENT | 1 |
| LP417663-4 | Nucleic acid amplification using Centers for Disease Control and Prevention primer-probe set N3 | METHOD | 2 |
| LP417664-2 | Patient health questionnaire 8 item | COMPONENT | 1 |
| LP417665-9 | Patient health questionnaire 8 item total score | COMPONENT | 1 |
| LP417666-7 | Lactobacillus crispatus+gasseri+jensenii + Gardnerella vaginalis + Atopobium vaginae | COMPONENT | |
| LP417667-5 | Lactobacillus crispatus+gasseri+jensenii + Gardnerella vaginalis + Atopobium vaginae rRNA | COMPONENT | 1 |
| LP417672-5 | Medical Aid in Dying | Document.SubjectMatterDomain | 13 |
| LP417673-3 | Mycobacterial stain and culture panel | COMPONENT | 1 |
| LP417675-8 | Lysosomal storage disorders panel | COMPONENT | 1 |
| LP417682-4 | Age when first smoked part or all of a cigarette | COMPONENT | 1 |
| LP417683-2 | Age when first started smoking cigarettes fairly regularly | COMPONENT | 1 |
| LP417684-0 | Number of HPV doses received | COMPONENT | 1 |
| LP417685-7 | Age when received human papillomavirus vaccination | COMPONENT | 1 |
| LP417686-5 | Collection procedure comment | COMPONENT | 1 |
| LP417687-3 | Processing comment | COMPONENT | 1 |
| LP417691-5 | Relationship to individual with confirmed or suspected illness | COMPONENT | 1 |
| LP417692-3 | Household contacts | COMPONENT | 1 |
| LP417693-1 | Leprosy | COMPONENT | 1 |
| LP417695-6 | Candida albicans, C. dubliniensis, C. parapsilosis, and C. tropicalis | COMPONENT | |
| LP417697-2 | Protoporphyrin fractions panel | COMPONENT | 1 |
| LP417698-0 | Arsenite | COMPONENT | 1 |
| LP417699-8 | Arsenobetaine | COMPONENT | 1 |
| LP417700-4 | Arsenocholine | COMPONENT | 1 |
| LP417701-2 | Dimethylarsinate | COMPONENT | 1 |
| LP417702-0 | Monomethylarsonate | COMPONENT | 1 |
| LP417703-8 | Enterocytozoon bieneusi 18S rRNA gene | COMPONENT | 1 |
| LP417704-6 | Encephalitozoon sp 18S rRNA gene | COMPONENT | 1 |
| LP417705-3 | HLA-A and B and C (class I) IgG intermediate risk | COMPONENT | 1 |
| LP417706-1 | HLA-A and B and C (class I) IgG low risk | COMPONENT | 1 |
| LP417715-2 | HLA-DP and DQ and DR (class II) IgG intermediate risk | COMPONENT | 1 |
| LP417716-0 | HLA-DP and DQ and DR (class II) IgG low risk | COMPONENT | 1 |
| LP417717-8 | Smoked at least 100 cigarettes in entire life | COMPONENT | 1 |
| LP417718-6 | HLA-DRB3 and HLA-DRB4 and HLA DRB5 IgG | COMPONENT | 1 |
| LP417722-8 | Mycobacterial identification panel | COMPONENT | 1 |
| LP417729-3 | corrected | CHALLENGE | |
| LP417742-6 | 24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 ratio panel | DIVISORS | |
| LP417746-7 | Alpha defensins 1+2+3 | COMPONENT | 1 |
| LP417747-5 | Tetanus reaction wheal | COMPONENT | |
| LP417748-3 | Tetanus reaction wheal^1 day post tetanus toxoid intradermal | COMPONENT | 1 |
| LP417749-1 | Tetanus reaction wheal^2 day post tetanus toxoid intradermal | COMPONENT | 1 |
| LP417750-9 | 2 day post tetanus toxoid intradermal | CHALLENGE | |
| LP417751-7 | 1 day post tetanus toxoid intradermal | CHALLENGE | |
| LP417752-5 | Reaction wheal^1D post control ID | COMPONENT | 1 |